Literature DB >> 9008160

p62(dok): a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells.

N Carpino1, D Wisniewski, A Strife, D Marshak, R Kobayashi, B Stillman, B Clarkson.   

Abstract

Characteristic of chronic myelogenous leukemia (CML) is the presence of the chimeric p210(bcr-abl) protein possessing elevated protein tyrosine kinase activity relative to normal c-abl tyrosine kinase. Hematopoietic progenitors isolated from CML patients in the chronic phase contain a constitutively tyrosine-phosphorylated protein that migrates at 62 kDa by SDS-PAGE and associates with the p120 ras GTPase-activating protein (GAP). We have purified p62(dok) from a hematopoietic cell line expressing p210(bcr-abl). p62(dok) is a novel protein with features of a signaling molecule. Association of p62(dok) with GAP correlates with its tyrosine phosphorylation. p62(dok) is rapidly tyrosine-phosphorylated upon activation of the c-Kit receptor, implicating it as a component of a signal transduction pathway downstream of receptor tyrosine kinases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9008160     DOI: 10.1016/s0092-8674(00)81840-1

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  89 in total

Review 1.  Small GTPases in lymphocyte biology: Rho proteins take center stage.

Authors:  S Henning; S Cleverley
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  Dok-3, a novel adapter molecule involved in the negative regulation of immunoreceptor signaling.

Authors:  S Lemay; D Davidson; S Latour; A Veillette
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

Review 3.  Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance.

Authors:  A Virkamäki; K Ueki; C R Kahn
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

4.  The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase.

Authors:  C R Maroun; M Holgado-Madruga; I Royal; M A Naujokas; T M Fournier; A J Wong; M Park
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

5.  The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase.

Authors:  C R Maroun; M A Naujokas; M Holgado-Madruga; A J Wong; M Park
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

6.  Inhibition of the motility and growth of B16F10 mouse melanoma cells by dominant negative mutants of Dok-1.

Authors:  T Hosooka; T Noguchi; H Nagai; T Horikawa; T Matozaki; M Ichihashi; M Kasuga
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

7.  Distinct recruitment and function of Gab1 and Gab2 in Met receptor-mediated epithelial morphogenesis.

Authors:  Lisa S Lock; Christiane R Maroun; Monica A Naujokas; Morag Park
Journal:  Mol Biol Cell       Date:  2002-06       Impact factor: 4.138

8.  Dok-1 independently attenuates Ras/mitogen-activated protein kinase and Src/c-myc pathways to inhibit platelet-derived growth factor-induced mitogenesis.

Authors:  Mingming Zhao; Justyna A Janas; Masaru Niki; Pier Paolo Pandolfi; Linda Van Aelst
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

9.  Detection of homo- or hetero-association of Doks by fluorescence resonance energy transfer in living cells.

Authors:  Feng Zhang; Guo Fu; Chen Wang; Li Cao; Hua-Yan Yang; Gui-Ying Wang; Yi-Zhang Chen; Cheng He
Journal:  Mol Imaging Biol       Date:  2008-11-25       Impact factor: 3.488

10.  IkappaB kinase beta phosphorylates Dok1 serines in response to TNF, IL-1, or gamma radiation.

Authors:  Sanghoon Lee; Charlotte Andrieu; Frédéric Saltel; Olivier Destaing; Jessie Auclair; Véronique Pouchkine; Jocelyne Michelon; Bruno Salaun; Ryuji Kobayashi; Pierre Jurdic; Elliott D Kieff; Bakary S Sylla
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.